Colon Cancer Panel with IHC

Description

(KRAS, NRAS, BRAF mutation analysis + Her2 and MSI by IHC)

Tissue, NA, Fasting or Non Fasting: As suggested by doctor

Sample Required:

FFPE colorectal tumour tissue block OR fresh tissue in DCGL Preservative Solution at 2–8°C.

Test Time:

Biopsy-dependent. 8–12 working days.

Test Normal Range:

No fixed normal range.

What is the Test?

A combined panel assessing **KRAS, NRAS, BRAF mutations**, with **HER2 and MSI** evaluated via IHC.

Test Procedure:

Tumour tissue undergoes sequencing plus dual IHC analysis.

When to Take the Test:

When mutation profiling plus immunophenotyping is required.

Who Should Take This Test:

Patients with colorectal cancer needing mutation and MSI/Her2 status.

Precautions for Exceptional Cases (Pregnancy, etc.):

Ensure tumour block adequacy; disclose pregnancy status.